...
首页> 外文期刊>Canadian Journal of Physiology and Pharmacology >A primer on current progress in cardiac fibrosis
【24h】

A primer on current progress in cardiac fibrosis

机译:心肌纤维化目前进展的底漆

获取原文
获取原文并翻译 | 示例
           

摘要

Cardiac fibrosis is a significant global health problem that is closely associated with multiple forms of cardiovascular disease, including myocardial infarction, dilated cardiomyopathy, and diabetes. Fibrosis increases myocardial wall stiffness due to excessive extracellular matrix deposition, causing impaired systolic and diastolic function, and facilitating arrhythmogenesis. As a result, patient morbidity and mortality are often dramatically elevated compared with those with cardiovascular disease but without overt fibrosis, demonstrating that fibrosis itself is both a pathologic response to existing disease and a significant risk factor for exacerbation of the underlying condition. The lack of any specific treatment for cardiac fibrosis in patients suffering from cardiovascular disease is a critical gap in our ability to care for these individuals. Here we provide an overview of the development of cardiac fibrosis, and discuss new research directions that have recently emerged and that may lead to the creation of novel treatments for patients with cardiovascular diseases. Such treatments would, ideally, complement existing therapy by specifically focusing on amelioration of fibrosis.
机译:心肌纤维化是一个重要的全球健康问题,与多种形式的心血管疾病密切相关,包括心肌梗塞,扩张心肌病和糖尿病。由于过度的细胞外基质沉积,纤维化增加了心肌壁刚度,导致收缩系统和舒张功能受损,促进心律失常。结果,与患有心血管疾病的人相比,患者的发病率和死亡率通常会显着升高,但没有明显的纤维化,证明纤维化本身是对现有疾病的病理反应和显着的危险因素,用于加剧潜在条件的恶化。患有心血管疾病的患者缺乏任何特异性治疗心肌纤维化是我们照顾这些人的关键差距。在这里,我们提供了心肌纤维化的发展概述,并讨论了最近出现的新研究方向,可能导致对心血管疾病患者的新疗法产生新的治疗方法。理想情况下,这种治疗将通过专门关注纤维化的改善来补充现有的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号